For research use only. Not for use in humans.

Monalizumab (Anti-Human CD159a)

Synonyms: Klrc1, NKG2A

Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.

Monalizumab (Anti-Human CD159a)

Click to purchase the isotype control of Monalizumab (Anti-Human CD159a)

3 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A205303 Purity: 99% Protein concentration: 7.72mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.
References

Product Details

CAS No. 1228763-95-8
Molecular Weight 150 kDa
Isotype Human IgG4-Kappa
Application Monalizumab (Anti-Human CD159a)
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05061550 RECRUITING Drug: Durvalumab|Drug: Oleclumab|Drug: Monalizumab|Drug: Dat Non-small Cell Lung Cancer AstraZeneca 2022-04-14 PHASE2
NCT05903092 RECRUITING Drug: Durvalumab|Drug: Monalizumab|Drug: Carboplatin or Cisp Small Cell Lung Cancer; SCLC; Extensive Stage Small Cell Lung Cancer; Limited Stage Small-Cell Lung Cancer Hirva Mamdani 2023-09-26 PHASE2
NCT06769126 RECRUITING Drug: Ceralasertib|Drug: Etoposide|Drug: Platinum Compound|D Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype; Lung Small Cell Carcinoma, I Subtype; Lung Small Cell Carcinoma, N Subtype; Lung Small Cell Carcinoma, P Subtype SWOG Cancer Research Network 2025-11-06 PHASE2
NCT06152523 WITHDRAWN Drug: Monalizumab/MEDI5257 MSI; dMMR Colorectal Cancer Assistance Publique - Hôpitaux de Paris 2023-12 PHASE2
NCT07146230 NOT_YET_RECRUITING Drug: Durvalumab|Drug: Monalizumab|Drug: Oleclumab Non-small Cell Lung Cancer Montefiore Medical Center 2026-09 PHASE2
NCT06503614 RECRUITING Drug: Durvalumab|Drug: Monalizumab Non-muscle Invasive Bladder Cancer; Non-Muscle Invasive Bladder Urothelial Carcinoma John Sfakianos 2025-02-24 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-21)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.